ISPOR PUBLISHES NEW GLOBAL HEALTH CARE SYSTEMS ROAD MAP- AUSTRALIA MEDICAL DEVICES

Published May 2, 2016
Princeton, NJ—May 2, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Australia Medical Devices. ISPOR’s Global Health Care Systems Road Maps provide an overview of country-specific, health care delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of three segments—pharmaceutical, medical devices, or diagnostics. The Global Health Care Systems Road Maps can benefit a variety of stakeholders (i.e., health care decision makers, payers, researchers, industry, clinicians, patient representatives, academicians, and students) who are interested in how a given country reimburses and approves pricing for health care technologies. These Road Maps are validated by country-specific health care experts and are periodically updated to reflect changes in the country’s health care delivery system. According to the newly published Global Health Care Systems Road Map—Australia Medical Devices, Australia has a publically funded universal health care system operated by the government’s Department of Health (DoH). Their aim is to provide universal access to all 23.5 million Australian citizens and permanent residents at an affordable or no cost. Medical devices are often referred to as “medical services” in Australia. Australia’s Therapeutic Goods Administration (TGA) is the regulatory body that is involved in many stages of the life cycle of a new medical device before and after it achieves market access in Australia. The ISPOR Global Health Care Systems Road Map—Australia Medical Devices can be found here. Other recently published Global Health Care Systems Road Maps include: Additional information on all of the ISPOR Tools for Health Care Decision Makers can be found here.

###

Related Stories

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.

ISPOR Champions Research Transparency With Launch of Open Science Badges

Aug 4, 2025

ISPOR introduced an initiative to recognize transparency in research for papers published in Value in Health, its preeminent HEOR journal.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×